Dr. Veneris is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215Phone+1 617-632-5269
Education & Training
- University of ChicagoResidency, Internal Medicine, 2012 - 2014
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2012
Certifications & Licensure
- MA State Medical License 2018 - 2025
- NH State Medical License 2024 - 2024
- IL State Medical License 2014 - 2020
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 151 citationsSafety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or profi...Ana Oaknin, Lucy Gilbert, Anna V Tinker, Jubilee Brown, Cara Mathews
Journal for Immunotherapy of Cancer. 2022-01-01 - 19 citationsAntitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.Thierry André, Dominique Berton, Giuseppe Curigliano, Renaud Sabatier, Anna V Tinker
JAMA Network Open. 2023-11-01 - 358 citationsCurrent recommendations and recent progress in endometrial cancer.Rebecca A. Brooks, Gini F. Fleming, Ricardo R. Lastra, Nita K. Lee, John W. Moroney
CA. 2019-07-01
Press Mentions
- Clinical Trial: Mirvetuximab Soravtansine and Pembrolizumab in Endometrial CancerOctober 26th, 2020
- SGO Issues May 18, 2017May 18th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: